Sugi Predict

Sugi Predict / Compounds / SCHEMBL9939767

SCHEMBL9939767

SCHEMBL9939767

CC(C)(C)CN/C(=N/C(=O)c1ccc(Cl)cc1)Nc1cccc(NS(=O)(=O)c2ccccc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ KDM4E B2RXH2 4/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.40
▸ TDP1 Q9NUW8 2/20 0.39
▸ LMNA P02545 2/20 0.38
▸ MYLK Q15746 1/20 0.38
▸ POLB P06746 2/20 0.38
▸ PPARA Q07869 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ BLM P54132 1/20 0.38
▸ IDH1 O75874 2/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ HDAC3 O15379 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16621987 0.90 NAMPT (0.42) HSD11B1MEN1KMT2AL3MBTL1KDM4E
SCHEMBL9939437 0.89 RXFP1 (0.39) HSD11B1MEN1KMT2AL3MBTL1KDM4E
SCHEMBL9939768 0.88 RXFP1 (0.43) HSD11B1L3MBTL1ALDH1A1HPGDRXFP1
SCHEMBL16621985 0.87 FBP1 (0.38) HSD11B1L3MBTL1RXFP1LMNA
SCHEMBL16621982 0.84 RXFP1 (0.40) HSD11B1L3MBTL1ALDH1A1RXFP1PPARA
SCHEMBL9939557 0.84 RXFP1 (0.47) MEN1KMT2AKDM4EALDH1A1RXFP1
SCHEMBL9939755 0.84 SCN9A (0.41) HSD11B1L3MBTL1KDM4EALDH1A1RXFP1
SCHEMBL16621984 0.83 RXFP1 (0.46) MEN1KMT2AALDH1A1RXFP1LMNA
SCHEMBL16621981 0.77 RXFP1 (0.42) HSD11B1MEN1KMT2AL3MBTL1RXFP1
SCHEMBL16621988 0.73 NAMPT (0.40) MEN1KMT2AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9370507-B2 Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2016-06-21 — — US disclosed
US-9370507-B2 Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2016-06-21 — — US disclosed
US-20150335625-A1 PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2015-11-26 — — US disclosed
US-20150335625-A1 PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2015-11-26 — — US disclosed
US-9000014-B2 Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-04-07 — — US disclosed
US-9000014-B2 Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-04-07 — — US disclosed
WO-2012078869-A1 PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335625-A1 PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF ATP5F1A, ATP5ME, ATP5F1B HSD11B1 4602/4885MEN1 3119/4885KMT2A 3290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.